

## Alexa Fluor<sup>®</sup> 700 anti-mouse CD45.2 Antibody

<b>Catalog# / Size</b>	109821 / 25 µg 109822 / 100 µg
<b>Clone</b>	104
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Ly-5.2, LCA
<b>Isotype</b>	Mouse (SJL) IgG2a, κ
<b>Description</b>	CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Immunogen</b>	B10.S mouse thymocytes and splenocytes
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor <sup>®</sup> 700 under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. The suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Alexa Fluor<sup>®</sup> 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor<sup>®</sup> 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.</p> <p>Alexa Fluor<sup>®</sup> and Pacific Blue™ are trademarks of Life Technologies Corporation.</p> <p><a href="#">View full statement regarding label licenses</a></p>
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>4</sup> , <i>in vivo</i> and <i>in vitro</i> blocking of B cell responses <sup>1,2</sup> , and immunohistochemical staining of acetone-fixed frozen sections <sup>3</sup> .
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Yakura H, <i>et al.</i> 1983. <i>J. Exp. Med.</i> 157:1077. (Block)</li> <li>2. Yakura H, <i>et al.</i> 1986. <i>J. Immunol.</i> 136:2729. (Block)</li> <li>3. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691. (IHC)</li> <li>4. Shen FW, <i>et al.</i> 1986. <i>Immunogenetics</i> 24:146. (IP)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

5. Baldwin TA and Hogquist KA. 2007. *J. Immunol.* 179:837.
6. Pascal V, *et al.* 2007. *J. Immunol.* 179:1751.
7. Burman AC, *et al.* 2007. *Blood* 110:1064.
8. Kincaid EZ, *et al.* 2007. *J. Immunol.* 179:3187.
9. Phan TG, *et al.* 2007. *Nature Immunol.* 8:992.
10. Nakano-Yokomizo T, *et al.* 2011. *J. Exp Med.* 208:1661. [PubMed](#)
11. Wen T, *et al.* 2013. *PNAS.* 110:6067. [PubMed](#)
12. Kohlmeier JE, *et al.* 2008. *Immunity.* 29:101. (FC) [PubMed](#)

## Product Citations

1. Basu S, *et al.* 2013. *J Immunol Methods.* 396:163. [PubMed](#)
2. Bradley CP *et al.* 2017. *Cell host & microbe.* 22(5):697-704 . [PubMed](#)
3. Wu J *et al.* 2017. *Immunity.* 47(6):1114-1128 . [PubMed](#)
4. Chandran S, *et al.* 2020. *Front Immunol.* 11:787. [PubMed](#)
5. Kawabe T, *et al.* 2020. *Nat Commun.* 2.795833333. [PubMed](#)
6. Vella JL, *et al.* 2021. *Life Sci Alliance.* 4:. [PubMed](#)
7. Su Y, *et al.* 2022. *J Hematol Oncol.* 15:99. [PubMed](#)
8. Gern BH, *et al.* 2021. *Cell Host Microbe.* 29(4):594-606.e6. [PubMed](#)
9. Zinselmeyer B, *et al.* 2013. *J Exp Med.* 210:757. [PubMed](#)
10. Viny AD, *et al.* 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
11. Page N, *et al.* 2018. *Immunity.* 48:937. [PubMed](#)
12. Ferrere G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
13. Turner JS *et al.* 2018. *Cell reports.* 25(6):1395-1403 . [PubMed](#)
14. Kim TJ, *et al.* 2019. *Nat Commun.* 10:3258. [PubMed](#)
15. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201 . [PubMed](#)
16. Ersching J *et al.* 2017. *Immunity.* 46(6):1045-1058 . [PubMed](#)
17. Zhang J, *et al.* 2021. *MedComm (Beijing).* 2:256. [PubMed](#)
18. Plumlee CR, *et al.* 2020. *Cell Host Microbe.* 29(1):68-82.e5. [PubMed](#)
19. Semmrich M, *et al.* 2011. *Mucosal Immunol.* 0.3125. [PubMed](#)
20. Kang S, *et al.* 2011. *J Exp Med.* 208:747. [PubMed](#)
21. Böttcher JP, *et al.* 2018. *Cell.* 172:1022. [PubMed](#)
22. Blackburn CMR, *et al.* 2021. *Atherosclerosis.* 330:76. [PubMed](#)
23. Rao S, *et al.* 2017. *Cell.* 168(3):503-516.e12. [PubMed](#)
24. Liu X, *et al.* 2021. *eLife.* 0.4166666666666667. [PubMed](#)
25. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283 . [PubMed](#)
26. Louveau A, *et al.* 2018. *Nat Neurosci.* 21:1380. [PubMed](#)
27. Inoue D, *et al.* 2021. *Nat Genet.* 53:707. [PubMed](#)
28. Yoshimi A, *et al.* 2019. *Nature.* 574:273. [PubMed](#)
29. Ciecko AE, *et al.* 2019. *Cell Rep.* 29:3073. [PubMed](#)
30. Kretschmer B, *et al.* 2015. *Immunobiology.* 220: 964-975. [PubMed](#)
31. Panciera T, *et al.* 2016. *Cell Stem Cell.* 19:725-737. [PubMed](#)
32. Amor C, *et al.* 2020. *Nature.* 583:127. [PubMed](#)
33. He W *et al.* 2018. *Immunity.* 49(6):1175-1190 . [PubMed](#)
34. He J, *et al.* 2020. *Cell Reports.* 29(9):2718-2730.e6.. [PubMed](#)
35. Salei N, *et al.* 2020. *J Am Soc Nephrol.* 31:257. [PubMed](#)
36. DeFranco D 2014. *Proc Natl Acad Sci U S A.* 111:3224. [PubMed](#)
37. Zenke S, *et al.* 2020. *Immunity.* 52(2):313-327. [PubMed](#)
38. Di Genua C, *et al.* 2020. *Cancer Cell.* 37(5):690-704.e8.. [PubMed](#)
39. Fallet B, *et al.* 2020. *Cell Rep.* 30:1013. [PubMed](#)
40. Lagares D, *et al.* 2017. *Sci Transl Med.* 9:eaal3765. [PubMed](#)
41. Adams NM *et al.* 2018. *Immunity.* 48(6):1172-1182 . [PubMed](#)
42. Kleppe M *et al.* 2018. *Cancer cell.* 33(1):29-43 . [PubMed](#)
43. Kinkel SA, *et al.* 2022. *iScience.* 25:104684. [PubMed](#)
44. Trompette A, *et al.* 2022. *Mucosal Immunol.* .: [PubMed](#)
45. Amos J, *et al.* 2015. *J Virol.* 89: 9485-9498. [PubMed](#)
46. Wiedemann GM, *et al.* 2020. *Cell Rep.* 33:108498. [PubMed](#)
47. Li Y, *et al.* 2020. *Cell Stem Cell.* 27(5):732-747.e7. [PubMed](#)
48. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
49. Diaz-Salazar C, *et al.* 2020. *Cell Rep.* 32:108186. [PubMed](#)
50. Lee SS, *et al.* 2022. *Commun Biol.* 5:654. [PubMed](#)
51. Markey K, *et al.* 2014. *J Immunol.* 192:5426. [PubMed](#)
52. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
53. Patel S, *et al.* 2019. *Viruses.* 0.877083333. [PubMed](#)
54. Cohen SB *et al.* 2018. *Cell host & microbe.* 24(3):439-446 . [PubMed](#)
55. Booth CAG, *et al.* 2018. *Cancer Cell.* 33:274. [PubMed](#)
56. Luck H, *et al.* 2015. *Cell Metab.* 21 527 . [PubMed](#)
57. Kruta M, *et al.* 2021. *Cell Stem Cell.* .: [PubMed](#)
58. Zaid A, *et al.* 2017. *J Immunol.* 10.4049/jimmunol.1700571. [PubMed](#)
59. Zhang H, *et al.* 2019. *Mol Cell.* 76:110. [PubMed](#)
60. Horkova V, *et al.* 2020. *Cell Reports.* 30(5):1504-1514.e7.. [PubMed](#)
61. Duan H, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
62. Schilke RM, *et al.* 2020. *Immunohorizons.* 0.624305556. [PubMed](#)
63. XS R, *et al.* 2015. *Diabetes.* 64 90. [PubMed](#)
64. Denny JE, *et al.* 2019. *Sci Rep.* 2.786111111. [PubMed](#)
65. Port JR, *et al.* 2020. *J Virol.* 94:. [PubMed](#)
66. Nadrah K, *et al.* 2015. *PLoS One.* 10: 0136061. [PubMed](#)
67. Goldstein JM *et al.* 2019. *Cell reports.* 27(4):1254-1264 . [PubMed](#)
68. Lebel MÈ, *et al.* 2020. *Nat Commun.* 3.051388889. [PubMed](#)
69. Gamrekelashvili J, *et al.* 2021. *Bio Protoc.* 11:e4007. [PubMed](#)

70. Chen R, *et al.* 2021. *Cell Reports*. 34(7):108751. [PubMed](#)
71. Loo CS, *et al.* 2020. *Immunity*. 53:143. [PubMed](#)
72. Nabet BY *et al.* 2017. *Cell*. 170(2):352-366. [PubMed](#)
73. Vasamsetti SB, *et al.* 2018. *Immunity*. 49:93. [PubMed](#)
74. Kwok T, *et al.* 2022. *Front Aging*. 3:838943. [PubMed](#)
75. XX, *et al.* 2016. *J Immunol*. 197: 1683-1691. [PubMed](#)
76. Kurowska-Stolarska M, *et al.* 2016. *J Allergy Clin Immunol*. S0091-6749(16)31132-0. [PubMed](#)
77. Guendel F, *et al.* 2020. *Immunity*. 53(5):1015-1032.e8. [PubMed](#)
78. Chakraborty M, *et al.* 2021. *Cell Reports*. 34(2):108609. [PubMed](#)
79. Urata S, *et al.* 2018. *PLoS Pathog*. 14:e1007172. [PubMed](#)
80. Di Genua C, *et al.* 2019. *Haematologica*. 104:2215. [PubMed](#)
81. Gao Z, *et al.* 2022. *J Inflamm Res*. 15:3337. [PubMed](#)
82. Jing Y, *et al.* 2021. *Front Immunol*. 12:651860. [PubMed](#)
83. Rustenhoven J, *et al.* 2021. *Cell*. 184(4):1000-1016.e27. [PubMed](#)
84. Sebina I, *et al.* 2016. *PLoS Pathog*. 12:e1005999. [PubMed](#)
85. Wang Y, *et al.* 2020. *eLife*. 9:e57438. [PubMed](#)
86. Benci JL *et al.* 2016. *Cell*. 167(6):1540-1554. [PubMed](#)
87. Contreras NA, *et al.* 2019. *PLoS Pathog*. 15:e1007890. [PubMed](#)
88. Wilmore JR, *et al.* 2022. *Front Immunol*. 12:791095. [PubMed](#)
89. Hobbs BE, *et al.* 2021. *Pathogens*. 10: [PubMed](#)
90. Sheppard S, *et al.* 2021. *Cell Reports*. 35(9):109210. [PubMed](#)
91. Sparber F, *et al.* 2019. *Cell Host Microbe*. 25:389. [PubMed](#)
92. Loo Yau H, *et al.* 2021. *Molecular Cell*. 81(7):1469-1483.e8. [PubMed](#)
93. Iwanami N, *et al.* 2020. *iScience*. 23:101260. [PubMed](#)
94. Hildreth AD, *et al.* 2020. *STAR Protoc*. 1:100113. [PubMed](#)
95. Hidalgo San Jose L, *et al.* 2020. *Cell Rep*. 30:69. [PubMed](#)
96. Geary CD *et al.* 2018. *Cell reports*. 24(8):1949-1957. [PubMed](#)
97. Heyde A, *et al.* 2021. *Cell*. 184(5):1348-1361.e22. [PubMed](#)
98. Koyama M *et al.* 2019. *Immunity*. 51(5):885-898. [PubMed](#)
99. Mesin L, *et al.* 2020. *Cell*. 180(1):92-106.e11. [PubMed](#)
100. Leruste A, *et al.* 2020. *Cancer Cell*. 36(6):597-612.e8. [PubMed](#)
101. Kubli SP, *et al.* 2019. *Nat Commun*. 10:2678. [PubMed](#)
102. Aurélien Trompette *et al.* 2018. *Immunity*. 48(5):992-1005. [PubMed](#)

**RRID** AB\_493730 (BioLegend Cat. No. 109821)  
 AB\_493731 (BioLegend Cat. No. 109822)

## Antigen Details

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691.
<b>Gene ID</b>	<a href="#">19264</a>

## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

Biotin anti-mouse CD45.2, FITC anti-mouse CD45.2, PE anti-mouse CD45.2, Purified anti-mouse CD45.2, APC anti-mouse CD45.2, Alexa Fluor® 488 anti-mouse CD45.2, Alexa Fluor® 647 anti-mouse CD45.2, Pacific Blue™ anti-mouse CD45.2, Alexa Fluor® 700 anti-mouse CD45.2, APC/Cyanine7 anti-mouse CD45.2, PerCP anti-mouse CD45.2, PerCP/Cyanine5.5 anti-mouse CD45.2, PE/Cyanine7 anti-mouse CD45.2, Brilliant Violet 421™ anti-mouse CD45.2, Brilliant Violet 570™ anti-mouse CD45.2, Brilliant Violet 650™ anti-mouse CD45.2, Brilliant Violet 510™ anti-mouse CD45.2, Brilliant Violet 785™ anti-mouse CD45.2, Brilliant Violet 605™ anti-mouse CD45.2, Purified anti-mouse CD45.2 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45.2, Brilliant Violet 711™ anti-

mouse CD45.2, Alexa Fluor® 594 anti-mouse CD45.2, APC/Fire™ 750 anti-mouse CD45.2, TotalSeq™-A0157 anti-mouse CD45.2, TotalSeq™-B0157 anti-mouse CD45.2, TotalSeq™-C0157 anti-mouse CD45.2, Brilliant Violet 750™ anti-mouse CD45.2, Spark Blue™ 550 anti-mouse CD45.2, Spark NIR™ 685 anti-mouse CD45.2

## Product Data

---



C57BL/6 mouse splenocytes stained with 104 Alexa Fluor® 700

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587